Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Stock
Equities
6990
CNE1000062J1
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 447.20 HKD | -1.71% |
|
-4.73% | +14.02% |
| Capitalization | 90.59B 104B 13.32B 11.32B 10.36B 9.78B 18.23B 1,258B 18.4B 123B 47.89B 604B 49.97B 48.92B 2,086B | P/E ratio 2026 * |
-451x | P/E ratio 2027 * | 144x |
|---|---|---|---|---|---|
| Enterprise value | 87.4B 101B 12.85B 10.92B 9.99B 9.43B 17.59B 1,214B 17.75B 119B 46.21B 583B 48.22B 47.2B 2,013B | EV / Sales 2026 * |
32.3x | EV / Sales 2027 * | 19.3x |
| Free-Float |
59.59% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
| 1 day | -1.71% | ||
| 1 week | -4.73% | ||
| Current month | -4.73% | ||
| 1 month | -8.17% | ||
| 3 months | +5.67% | ||
| 6 months | +9.34% | ||
| Current year | +14.02% |
| 1 week | 444.4 |  | 488 |
| 1 month | 443.6 | | 529.5 |
| Current year | 339.6 | | 529.5 |
| 1 year | 296.2 | | 581 |
| 3 years | 60.6 | | 581 |
| 5 years | 60.6 | | 581 |
| 10 years | 60.6 | | 581 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jun You Ge
CEO | Chief Executive Officer | 54 | 2022-02-28 |
Ze Jian Zhou
DFI | Director of Finance/CFO | 43 | 2022-08-16 |
Xiang Yang Tan
CTO | Chief Tech/Sci/R&D Officer | 63 | 2021-07-04 |
| Director | Title | Age | Since |
|---|---|---|---|
Ge Xin Liu
CHM | Chairman | 75 | 2022-02-28 |
Jin Ping Jin
BRD | Director/Board Member | 54 | 2023-02-14 |
Yue Dong Li
BRD | Director/Board Member | 49 | 2023-02-14 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.71% | -4.73% | +36.01% | - | 13.32B | |
| -4.03% | -2.51% | +81.08% | +57.71% | 47.65B | |
| -0.06% | +0.42% | +37.94% | +83.93% | 49.1B | |
| +1.19% | -3.50% | -0.69% | -12.89% | 23.8B | |
| -3.48% | -23.95% | +54.43% | +436.24% | 21.97B | |
| -1.86% | -1.15% | +44.83% | -31.10% | 17.26B | |
| -6.65% | -3.10% | +27.25% | -40.24% | 15.88B | |
| -2.83% | -1.33% | +59.05% | +199.44% | 15.77B | |
| +5.42% | +12.19% | -26.65% | +831.96% | 14.03B | |
| -4.64% | -0.72% | +70.26% | +65.13% | 11.76B | |
| Average | -1.86% | -2.98% | +38.35% | +176.69% | 23.05B | |
| Weighted average by Cap. | -1.85% | -3.33% | +43.27% | +140.67% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.71B 3.12B 398M 338M 310M 292M 545M 37.63B 550M 3.67B 1.43B 18.07B 1.49B 1.46B 62.4B | 4.51B 5.19B 663M 563M 515M 487M 907M 62.61B 915M 6.11B 2.38B 30.07B 2.49B 2.43B 104B |
| Net income | -200M -230M -29.44M -25.01M -22.89M -21.6M -40.3M -2.78B -40.66M -272M -106M -1.34B -110M -108M -4.61B | 629M 724M 92.43M 78.53M 71.86M 67.83M 127M 8.73B 128M 852M 332M 4.19B 347M 339M 14.48B |
| Net Debt | -3.18B -3.67B -468M -398M -364M -344M -641M -44.22B -647M -4.32B -1.68B -21.24B -1.76B -1.72B -73.33B | -3.75B -4.32B -552M -469M -429M -405M -756M -52.14B -762M -5.09B -1.98B -25.05B -2.07B -2.03B -86.47B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-05-08 | 447.20 $ | -1.71% | 459,899 |
| 26-05-07 | 455.00 $ | -1.00% | 569,400 |
| 26-05-06 | 459.60 $ | +0.61% | 462,089 |
| 26-05-05 | 456.80 $ | -0.91% | 46,702 |
| 26-05-04 | 461.00 $ | -1.79% | 117,012 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 6990 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition